Skip to main content

Table 4 Tumor response by prior regimen in patients treated as second-line

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Tumor Response

Prior regimen (N = 20)

 

IP

FP

DP

NP

Complete response

0

0

0

1

Partial response

4

2

1

2

Stable disease

1

1

2

1

Progressive disease

2

0

3

0

Total

7

3

6

4

  1. Abbreviations: IP, Irinotecan/cisplatin; FP, 5-fluorouracil/cisplatin; DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin.